| pubmed-article:14974945 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14974945 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:14974945 | lifeskim:mentions | umls-concept:C0024501 | lld:lifeskim |
| pubmed-article:14974945 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:14974945 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:14974945 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:14974945 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:14974945 | lifeskim:mentions | umls-concept:C1337395 | lld:lifeskim |
| pubmed-article:14974945 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:14974945 | pubmed:dateCreated | 2004-2-20 | lld:pubmed |
| pubmed-article:14974945 | pubmed:abstractText | With the objective of enhancing upper gastrointestinal (GI) tolerability, enteric-coated mycophenolate sodium (EC-MPS, myfortic, Novartis Pharma AG, Basel, Switzerland) has been developed. This double-blinded, 12-month study investigated whether renal transplant patients taking mycophenolate mofetil (MMF) can be safely converted to EC-MPS. Stable kidney transplant patients were randomized to receive EC-MPS (720 mg b.i.d.; n=159) or continue receiving MMF (1000 mg b.i.d.; n=163). The incidence of GI adverse events (AEs) was similar at 3 months (primary endpoint: EC-MPS 26.4%; MMF 20.9%; p=NS) and at 12 months (EC-MPS 29.6%; MMF 24.5%; p=NS). The increase from baseline in mean GI AE severity score, adjusted for duration, tended to be lower in EC-MPS patients (3 months: 0.15 vs. 0.20; 12 months: 0.23 vs. 0.47; p=NS). Neutropenia (<1500 cells/mm3) within the first 3 months (coprimary endpoint) was low in both groups (EC-MPS 0.6%; MMF 3.1%; p=NS). Although the overall incidence of infections was similar, the number of serious infections was significantly lower in EC-MPS patients (8.8% vs. 16.0%; p<0.05). Similar rates of efficacy failure (EC-MPS 2.5%; MMF 6.1%; p=NS), biopsy-proven acute rejection (EC-MPS 1.3%; MMF 3.1%; p=NS) and biopsy-proven chronic rejection (EC-MPS 3.8%; MMF 4.9%; p=NS) were observed in both groups. In conclusion, renal maintenance patients can be converted from MMF to EC-MPS without compromising the safety and efficacy profile associated with MMF. | lld:pubmed |
| pubmed-article:14974945 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14974945 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14974945 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14974945 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14974945 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14974945 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14974945 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14974945 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14974945 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:14974945 | pubmed:issn | 1600-6135 | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:HallMichaelM | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:NeumayerHans-... | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:BuddeKlemensK | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:ChanLawrenceL | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:CurtisJohnJ | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:KnollGregoryG | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:SeifuYoditY | lld:pubmed |
| pubmed-article:14974945 | pubmed:author | pubmed-author:ERL B302... | lld:pubmed |
| pubmed-article:14974945 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14974945 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:14974945 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14974945 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14974945 | pubmed:pagination | 237-43 | lld:pubmed |
| pubmed-article:14974945 | pubmed:dateRevised | 2007-2-14 | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:meshHeading | pubmed-meshheading:14974945... | lld:pubmed |
| pubmed-article:14974945 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14974945 | pubmed:articleTitle | Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. | lld:pubmed |
| pubmed-article:14974945 | pubmed:affiliation | University Hospital Charité, Berlin, Germany. klemens.budde@charite.de | lld:pubmed |
| pubmed-article:14974945 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14974945 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14974945 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:14974945 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:14974945 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:14974945 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14974945 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14974945 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14974945 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14974945 | lld:pubmed |
